Drug Database
AL

alternaria allergen SLIT

✓ Approved

HAL Allergy Group · therapeutic agent

What is alternaria allergen SLIT?

alternaria allergen SLIT is a therapeutic agent developed by HAL Allergy Group. It is approved for therapeutic indications via oral (po) or sublingual (sl)/oral transmucosal.

Drug Profile

CompanyHAL Allergy Group
RouteOral (PO), Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, HAL Allergy Group

Therapeutic Indications

alternaria allergen SLIT is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Immune system disordersHypersensitivity✓ Approved

Related Research Articles

PubMedWorld journal of otorhinolaryngology - head and neck surgery2026-07-25

Enhanced Early Detection of Allergic Rhinitis: A Prospective Study on a Symptom-Based Predictive Model.

Zhu Ke-Zhang KZ, He Chao C, Zhu Si-Zhe SZ, Liu Zheng Z et al.

Allergic rhinitis (AR) and non-allergic rhinitis (NAR) share overlapping symptoms but differ in pathophysiology and treatment. Current AR diagnosis relies on skin prick testing (SPT) and serum IgE quantification, both of which are complex. This study aimed to develop a symptom-based model for early AR detection, explore allergen-symptom relationships, and evaluate its performance. A prospective cohort study was conducted at Wuhan Tongji Hospital between June 2024 and October 2024, enrolling 1150 patients with clinically suspected AR. Participants completed a visual analogue scale (VAS) questionnaire evaluating nasal symptoms (itching, congestion, sneezing, rhinorrhea), ocular symptoms, and overall discomfort, and the final diagnosis of AR was confirmed by SPT. Patients were randomly divided into training and test cohorts (8:2). Logistic regression (LR), the classic artificial intelligence-machine learning algorithm, was used to build a prediction model after analyzing allergen-symptom associations, with evaluation of discrimination, calibration, and clinical utility. A total of 758 patients (65.9%) were confirmed AR cases, and showed more severe nasal/ocular symptoms than NAR. Dust mites were the most common allergen, correlated with animal dander (r > 0.45) and negatively with age (r = -0.27), while allergen-symptom specificity was generally low. Sneezing was the strongest AR predictor (AUC = 0.758) with the highest sensitivity, specificity, and F1 score, and the multivariable model combining all symptoms performed better (AUC = 0.771 training, 0.765 test), outperforming clinician experience. The model showed good calibration and stable performance across subgroups. This study developed a symptom-based AR predictive model that outperformed clinician experience. Sneezing demonstrated the highest AUC value for prediction, and the multivariable LR model using nasal and ocular symptoms further improved accuracy. The findings support VAS-based screening as a practical, cost-effective tool for early AR detection, therapeutic interventions, and targeted patient education regarding allergen avoidance strategies, helping optimize AR management, minimizing diagnostic delays, and facilitating precision treatment decisions.

PMID 42500099
Read full article →
PubMedAnalytical and bioanalytical chemistry2026-07-25

Evaluation of almond and hazelnut reference materials for standardizing allergenic protein detection and quantification.

Kilpatrick Lisa E LE, Bunk David M DM, Phinney Karen W KW

Almonds and hazelnuts are widely consumed tree nuts; nevertheless, they are recognized by the U.S. Food and Drug Administration (FDA) and regulatory agencies in other countries as potential allergens requiring clear labeling on foods. While detecting these allergens during food production is essential, protein-based assays currently used to identify cross contact during food manufacturing often have variable results due to food processing effects, matrix interference, or antibody specificity. To address these challenges, the National Institute of Standards and Technology (NIST) Reference Materials (RMs) 8404 Almond Nut Flour for Allergen Detection and 8405 Hazelnut Flour for Allergen Detection were developed to harmonize detection methods. In this work, Dumas total protein assay and liquid chromatography-tandem mass spectrometry (LC-MS/MS) were used to characterize the protein composition of the NIST RMs along with other sources of nut flours. The RMs were next evaluated using commercial enzyme-linked immunosorbent assays (ELISAs) to assess their utility in standardizing the detection and quantification of total protein from almond and hazelnut flours. From these experiments, flours processed with different manufacturing methods were found to have similar recoveries for each ELISA only when quantifying total protein rather than total nut mass. Additionally, NIST RMs 8404 and 8405 were used to improve the reproducibility of protein recovery across commercial almond and hazelnut ELISA kits. These findings provide a framework for reporting ELISA results and using RMs to facilitate more reliable and standardized allergen risk management.

PMID 42498789
Read full article →
PubMedWorld journal of otorhinolaryngology - head and neck surgery2026-07-25

Cellular Mechanism and Key Insights in Allergen Immunotherapy for Allergic Rhinitis.

Wang Zhe Z, Li Teng-Fei TF, Wang Tian-Yu TY, Liu Huan-Hai HH

Allergic rhinitis (AR) arises from immune responses mediated by immunoglobulin E (IgE) to inhaled allergens, representing one of the most prevalent chronic conditions worldwide. Although AR may not be a serious ailment, it holds clinical relevance as it underpins numerous complications, serves as a major risk factor for suboptimal asthma control, and adversely affects quality of life and productivity in both work and school environments. Prevention and treatment strategies for AR encompass various approaches, including allergen avoidance, pharmacotherapy, allergen-specific immunotherapy (AIT), and patient education. Among the treatments for AR, AIT stands out as the only curative intervention. It offers a targeted and long-term solution by modifying the underlying immune response, providing lasting relief for individuals with AR. AIT, which targets individual allergens, is garnering increasing attention due to recent evidence from numerous randomized controlled trials and long-term real-life studies that attest to its effectiveness. By actively altering the immune response, AIT modifies the natural course of allergy, offering benefits that extend beyond the immediate symptom relief. In this updated review, we provide new insights into the roles of diverse immune cells involved in AIT for the treatment of AR. AIT inhibits FcεRⅠactivity, enhances epithelial function, reduces pro-inflammatory ILC2s while promoting immunoregulatory IL-10+ILC2s, augments regulatory DCreg subsets, and drives a shift from Th2 to Th1 immune responses. The objective of this review is to explore the fundamental principles and effectiveness of immunotherapy in the management of AR, as well as to showcase the latest developments in this area of research.

PMID 42500109
Read full article →
PubMedThe Journal of allergy and clinical immunology2026-07-25

Achieving disease modification with food allergy therapies: An international perspective.

Anagnostou Aikaterini A, Bégin Phillipe P, Eiwegger Thomas T, Greenhawt Matthew M et al.

A disease-modifying therapy aims to alter natural history by delaying or reversing disease progression. This rostrum examines expert opinion regarding the concept of disease modification in food allergy and contextualizes relevant definitions, such as desensitization, sustained unresponsiveness, tolerance, and remission. It evaluates evidence-based disease-modifying effects of current and emerging therapeutic strategies from clinical and immunological to patient-centered perspectives. Evidence from oral, epicutaneous and sublingual immunotherapy demonstrates that desensitization is common and that a subset of patients consistently achieve sustained unresponsiveness or remission after treatment discontinuation. Studies to date have noted that younger age and lower baseline allergen-specific IgE may predict more durable responses, although findings are inconsistent across populations and allergens. Immunologic changes associated with these outcomes include suppression of Type 2 cellular responses, modulation of B-cell compartments and induction of blocking antibodies, but no clear link to a specific clinical state can be claimed. Currently approved biologics enhance protection during active treatment, but have limited evidence for direct disease modification, although they may facilitate tolerance when combined with allergen exposure. Patient-reported outcomes, especially quality of life and self-efficacy remain critical yet underutilized measures of therapeutic benefit. Clinical trial designs face multiple challenges in evaluating long-term disease modification. While the clinical states of desensitization, sustained unresponsiveness, tolerance and remission may involve partial or complete disease modification in food allergy, no consensus definition exists or relevant biomarker has been identified to date. Future work will require harmonized definitions, innovative trial designs and therapies targeting long-lived immunological memory with continued emphasis on patient-centered outcomes and real-world clinical relevance.

PMID 42498123
Read full article →
PubMedJournal of vitreoretinal diseases2026-07-25

Diabetic Retinopathy Screening and Treatment Capacity in Student-Run Free Clinics: A National Assessment.

Larsen Jacob J, Sarwar Haider H, Fu Daniel D, Patnaik Jennifer L JL et al.

To characterize ophthalmic resources and evaluate diabetic retinopathy screening, treatment, and referral practices among student-run free clinics in the United States that provide ophthalmology services. A cross-sectional survey was distributed to 54 student-run free clinics identified through a national network. The 17-item survey assessed clinic demographics, funding sources, ophthalmic equipment availability, diabetic retinopathy screening and treatment practices, referral pathways, perceived barriers, and resource needs. Of the 54 clinics contacted, 21 (39%) responded, representing 13 states. All clinics reported caring for patients with diabetic retinopathy (100%), glaucoma (81%), and cataracts (76%). Primary funding sources included grants (38%) and alternative funding mechanisms (29%). Commonly available equipment included slit lamps (67%) and indirect ophthalmoscopes (52%), while advanced imaging modalities such as optical coherence tomography were available in only 14% of clinics. Diabetic retinopathy screening was performed in 95% of clinics, primarily via dilated retinal examination (55%). Only 14% of clinics (3/21) reported access to diabetic retinopathy treatment via external referral pathways, and none provided treatment on site. Key barriers to comprehensive care included insufficient funding, lack of diagnostic equipment, and limited availability of trained clinical personnel. Student-run free clinics commonly provide diabetic retinopathy screening but lack the capacity to deliver definitive treatment, relying primarily on external referral pathways. Strengthening academic partnerships and expanding treatment access may improve equitable, vision-preserving care for underserved populations.

PMID 42500199
Read full article →
PubMedZooKeys2026-07-25

A new earthworm species of the genus Eisenia Malm, 1877 (Oligochaeta, Lumbricidae) from the Ili River valley, northwestern China.

Xu Pingping P, Zhang Yufeng Y, Shu Xin X, Han Dayong D et al.

The present study focuses on the taxonomy of the earthworm genus Eisenia Ealm, 1877 in China. The taxonomic framework for this genus in China has long been ambiguous, with studies in the northwestern region being particularly scarce. Prior to this research, only four subspecies within the Eisenia nordenskioldi (Eisen, 1879) complex, distributed across northeastern and northern China, had been described. Based on detailed morphological characteristics and molecular data, this paper describes a new species, E. ilensis sp. nov., collected from the Ili River valley in northwestern China. The key diagnostic characteristics of this new species include a medium body length (37-103 mm); two pairs of small, spherical spermathecae without ducts, located at the inter-segmental furrows 9/10 and 10/11; a pair of small, circular tubercula pubertatis on the clitellum situated between the ab setae; the first of dorsal pore beginning at the 4/5 inter-segmental furrow; and a pair of slit-like male pores on segment XV. Phylogenetic analyses based on the mitogenomic protein coding genes indicate that E. ilensis sp. nov. forms a distinct clade with E. balatonica Pop, 1943 supporting its status as an independent species and a basal evolutionary status. The discovery of the new species of E. ilensis sp. nov. not only enriches the species diversity of the genus Eisenia in China but also provides a crucial taxonomic foundation for subsequent research into the evolution and dispersal history of this genus in Eurasia.

PMID 42500350
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about alternaria allergen SLIT